The cryopreservation of hematopoietic cells using dimethyl sulfoxide (DMSO) and serum is a common procedure used in transplantation. However, DMSO has clinical and biological side effects due to its toxicity, and serum introduces variation and safety risks. Explore the development of a novel class of ice-interactive cryoprotectants inspired by natural antifreeze proteins.
XT-Thrive is identified as a lead candidate to rival cryopreservation with 10% DMSO in serum based on post-thaw cell survival and short-term proliferation assays. Herein, novel cryoprotectants were tested on hematopoietic cells. The fully synthetic cryoprotectants control ice formation and are non-toxic, chemically stable, and are protein-free. Candidate formulations were compared to 10% DMSO in serum for use during liquid nitrogen storage (−196 °C).
Explore findings that show XT-Thrive can substitute the use of 10% DMSO and serum as a cryopreservation solution.